Literature DB >> 29160731

Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.

Carlyn Rose C Tan1, Stefan K Barta1, Jeannette Lee2, Michelle A Rudek3, Joseph A Sparano4, Ariela Noy5.   

Abstract

Drug-drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034, HIV-associated high-grade B-cell NHL patients received DA-EPOCH with rituximab. cART was given with EPOCH or delayed until chemotherapy completion per investigator choice. Pharmacokinetic, immunological, and treatment effects of concurrent cART were evaluated. CD4 counts dropped during EPOCH in both groups but recovered to higher than baseline 6 months post-EPOCH only in the cART group. HIV viral load decreased during chemotherapy in the cART group but increased in the non-cART group. Incidence of grade ≥3 infectious, hematologic, or neurological toxicities was similar. Concurrent cART was not associated with 1-year EFS or OS. cART with EPOCH was well-tolerated and allowed for faster immune recovery. While we did not observe differences in outcome, the preponderance of evidence is in favor of combining cART with chemotherapy.

Entities:  

Keywords:  AIDS; HIV; HIV-associated lymphoma; chemotherapy; combination antiretroviral therapy; dose-adjusted EPOCH

Mesh：

Substances：

Year:  2017        PMID： 29160731      PMCID： PMC5962410          DOI： 10.1080/10428194.2017.1403597

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


  35 in total

Review 1.  Update in HIV lymphoma.

Authors:  Ariela Noy
Journal:  Curr Opin Oncol       Date:  2006-09       Impact factor: 3.645

Review 2.  HIV-associated lymphoma: the evidence for treating aggressively but with caution.

Authors:  Joseph A Sparano
Journal:  Curr Opin Oncol       Date:  2007-09       Impact factor: 3.645

3.  Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.

Authors:  Andrés J M Ferreri; Marta Bruno Ventre; Giovanni Donadoni; Chiara Cattaneo; Luca Fumagalli; Marco Foppoli; Silvia Mappa; Silvia Govi; Massimo Di Nicola; Giuseppe Rossi; Umberto Tirelli; Federico Caligaris-Cappio; Michele Spina; Alessandro Re
Journal:  Br J Haematol       Date:  2012-08-25       Impact factor: 6.998

4.  HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era.

Authors:  Rita Coutinho; Alessia D Pria; Shreyans Gandhi; Katharine Bailey; Paul Fields; Kate Cwynarski; Andrew Wilson; Panagiotis Papanastasopoulos; Melinda Tenant-Flowers; Andrew Webb; Fiona Burns; Robert E Marcus; Chloe Orkin; Silvia Montoto; Mark Bower
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

Review 5.  Pharmacogenomics knowledge for personalized medicine.

Authors:  M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2012-10       Impact factor: 6.875

Review 6.  Update on the treatment of HIV-associated hematologic malignancies.

Authors:  Richard F Little; Kieron Dunleavy
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

7.  Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.

Authors:  A Antinori; A Cingolani; L Alba; A Ammassari; D Serraino; B C Ciancio; F Palmieri; A De Luca; L M Larocca; L Ruco; G Ippolito; R Cauda
Journal:  AIDS       Date:  2001-08-17       Impact factor: 4.177

8.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

9.  Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.

Authors:  Humphrey J Shao; John A Crump; Habib O Ramadhani; Leonard O Uiso; Sendui Ole-Nguyaine; Andrew M Moon; Rehema A Kiwera; Christopher W Woods; John F Shao; John A Bartlett; Nathan M Thielman
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

10.  Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma.

Authors:  Mark Bower; Justin Stebbing; Mark Tuthill; Victoria Campbell; Johnathan Krell; Paul Holmes; Andrew Ozzard; Mark Nelson; Brian Gazzard; Tom Powles
Journal:  Blood       Date:  2008-01-02       Impact factor: 22.113
View more
  7 in total

Review 1.  Optimizing treatment of HIV-associated lymphoma.

Authors:  Ariela Noy
Journal:  Blood       Date:  2019-10-24       Impact factor: 22.113

2.  Risks of Opportunistic Infections in People With Human Immunodeficiency Virus With Cancers Treated With Chemotherapy.

Authors:  Alain Makinson; Lesley S Park; Kimberly Stone; Janet Tate; Maria C Rodriguez-Barradas; Sheldon T Brown; Roxanne Wadia; Kristina Crothers; Roger Bedimo; Matthew Bidwell Goetz; Fatma Shebl; Jacques Reynes; Vincent Le Moing; Keith M Sigel
Journal:  Open Forum Infect Dis       Date:  2021-07-19       Impact factor: 3.835

Review 3.  HIV Lymphoma and Burkitts Lymphoma.

Authors:  Ariela Noy
Journal:  Cancer J       Date:  2020 May/Jun       Impact factor: 2.074

4.  The clinical features and prognosis of 100 AIDS-related lymphoma cases.

Authors:  Dedong Wu; Chen Chen; Mingzhi Zhang; Zhaoming Li; Suqian Wang; Jijing Shi; Yu Zhang; Dingzhu Yao; Shuang Hu
Journal:  Sci Rep       Date:  2019-03-29       Impact factor: 4.379

5.  [Primary effusion lymphoma in a HIV-negative patient: case report and literatures review].

Authors:  Y F Song; H Liu; J F Bai; H X Ke; J T Li; T Wang; Y Z Yang; J J Yin; R Feng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

Review 6.  Primary Effusion Lymphoma: A Clinicopathologic Perspective.

Authors:  Diamone A Gathers; Emily Galloway; Katalin Kelemen; Allison Rosenthal; Sarah E Gibson; Javier Munoz
Journal:  Cancers (Basel)       Date:  2022-01-30       Impact factor: 6.639

7.  Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China.

Authors:  Chaoyu Wang; Jun Liu; Haike Lei; Yu Li; Jian Wu; Bingling Guo; Renzhi Hu; Tingting Liu; Jing Wu; Yao Ding; Chongling Hu; Shunsi Liang; Chunyan Xiao; Xiping Liang; Dehong Huang; Tao Yang; Wenjun Zhang; Zailin Yang; Jieping Li; Yingyu Nan; Qiying Li; Ying Xiang; Zhenhua Li; Yongzhong Wu; Yao Liu
Journal:  J Cell Mol Med       Date:  2022-09-03       Impact factor: 5.295
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.